Literature DB >> 2837016

Participation of cytoskeletal intermediate filaments in the infectious cycle of human respiratory syncytial virus (RSV).

B Garcia-Barreno1, J L Jorcano, T Aukenbauer, C López-Galíndez, J A Melero.   

Abstract

RSV infection of Hep-2 or HeLa cells leads to biochemical and morphological changes of cytoskeletal intermediate filaments (IF). Thus, human cytokeratin 18 is modified to generate a more acidic polypeptide of slightly larger apparent molecular weight. In addition, the amounts of vimentin and other cytokeratins are reduced, probably as a consequence of proteolytic degradation. These changes are reflected in a decrease of immunofluorescence with specific antibodies in RSV-induced syncytia and a more disorganized arrangement of IF arrays. About 50% of virus nucleoprotein (NP) is extracted with the high salt and detergent-insoluble intermediate filament fraction. Pulse-chase experiments indicate that NP needs a maturation period after synthesis to associate with IF. It is suggested that RSV needs to interact with IF during its life cycle and that association of NP, and/or other viral components, with IF might then lead to cytoskeletal structures becoming unstable in RSV-infected cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2837016     DOI: 10.1016/0168-1702(88)90090-1

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  19 in total

1.  RhoA interacts with the fusion glycoprotein of respiratory syncytial virus and facilitates virus-induced syncytium formation.

Authors:  M K Pastey; J E Crowe; B S Graham
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion.

Authors:  L González-Reyes; M B Ruiz-Argüello; B García-Barreno; L Calder; J A López; J P Albar; J J Skehel; D C Wiley; J A Melero
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-07       Impact factor: 11.205

3.  Transcription of human respiratory syncytial virus genome RNA in vitro: requirement of cellular factor(s).

Authors:  S Barik
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

4.  Premature stop codons in the G glycoprotein of human respiratory syncytial viruses resistant to neutralization by monoclonal antibodies.

Authors:  P Rueda; T Delgado; A Portela; J A Melero; B García-Barreno
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

5.  Defining the cellular target(s) of porcine reproductive and respiratory syndrome virus blocking monoclonal antibody 7G10.

Authors:  Jeong-Ki Kim; Al-Majhdi Fahad; Kumar Shanmukhappa; Sanjay Kapil
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  Onset of human cytomegalovirus replication in fibroblasts requires the presence of an intact vimentin cytoskeleton.

Authors:  Matthew S Miller; Laura Hertel
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

7.  Induction of a neutralizing immune response to human respiratory syncytial virus with anti-idiotypic antibodies.

Authors:  C Palomo; J P Albar; B García-Barreno; J A Melero
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

8.  Interaction of Theiler's virus with intermediate filaments of infected cells.

Authors:  P Nédellec; P Vicart; C Laurent-Winter; C Martinat; M C Prévost; M Brahic
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

9.  Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins.

Authors:  B García-Barreno; C Palomo; C Peñas; T Delgado; P Perez-Breña; J A Melero
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

10.  Identification of protein regions involved in the interaction of human respiratory syncytial virus phosphoprotein and nucleoprotein: significance for nucleocapsid assembly and formation of cytoplasmic inclusions.

Authors:  B García-Barreno; T Delgado; J A Melero
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.